Having received European clearance 3 months ago, Hutchinson Technology‘s InSpectra StO2 Spot Check (model 300) has now received FDA regulatory approval for determining tissue oxygenation in those experiencing circulatory distress. As we noted last time, the device allows direct measurement of oxygen saturation in microcirculation, where oxygen is exchanged with tissues, hence it could be used for evaluation of regional, maybe even systemic perfusion in critically ill, in septic shock, etc.
The InSpectra StO2 Spot Check (model 300) consists of a hand-held device, cable, reusable sensor, charging station and rechargeable battery. This product enables clinicians to quickly and cost-effectively identify at-risk patients. Once identified as having low StO2, patients can then be continuously monitored with the InSpectra(TM) StO2 Tissue Oxygenation Monitor (model 650). These two products help reduce the time to critical actions and identify the endpoints of resuscitation.
Press release: Hutchinson Technology Announces FDA Clearance of the InSpectra™ StO2 Spot Check…
Product page: InSpectra StO2 Spot Check (model 300)…
Flashback: InSpectra StO2 Spot Check Tissue Perfusion Monitor Gets European Clearance